Express News | Context Therapeutics 13G Filing Shows Great Point Partners, LLC Reported A 9.89% Stake In The Co As Of May 31, 2024
Express News | Great Point Partners, LLC Reports Passive Stake of 9.89% in Context Therapeutics as of May 31, 2024 - SEC Filing
Express News | Nextech Crossover I Scsp Reports 9.9% Passive Stake in Context Therapeutics as of May 6- SEC Filing
Context Therapeutics Files Prospectus for Secondary Offering
Context Therapeutics (CNTX) on Friday filed a registration statement with the US Securities and Exchange Commission for the sale of up to 64.5 million common shares by selling stockholders from time t
Express News | Context Therapeutics Files for Shelf of up to 64.5 Mln Shares of Common Stock by Selling Stockholders - SEC Filing
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) Is a Great Choice
Context Therapeutics Price Target Announced at $4.50/Share by Piper Sandler
Context Therapeutics Price Target Announced at $4.50/Share by Piper Sandler
Express News | Piper Sandler Initiates Coverage On Context Therapeutics With Overweight Rating, Announces Price Target of $4.5
Optimistic Outlook for Context Therapeutics' CTIM-76 Based on Targeting Efficacy and Market Potential
Express News | Context Therapeutics 13G Filing Shows Avidity Partners Management LP Reported A 9.9% Stake In The Co As Of May 2, 2024
Express News | Avidity Partners Management LP Reports 9.9% Passive Stake in Context Therapeutics as of May 2- SEC Filing
Express News | Deep Track Capital Reports Passive Stake Of 9.89% In Context Therapeutics As Of May 2, 2024
Express News | Deep Track Capital, LP Reports Passive Stake of 9.89% in Context Therapeutics as of May 2, 2024- SEC Filing
Context Therapeutics Price Target Raised to $5.00/Share From $4.00 by HC Wainwright & Co.
Context Therapeutics Price Target Raised to $5.00/Share From $4.00 by HC Wainwright & Co.
Context Therapeutics Is Maintained at Buy by Maxim Group
Context Therapeutics Is Maintained at Buy by Maxim Group
Express News | Maxim Group Maintains Buy on Context Therapeutics, Raises Price Target to $10
Context Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 449.45% Maxim Group $4 → $10 Maintains Buy 03/21/2024 119.78% HC Wainwright & Co. $5 → $4 Maint
Promising Clinical Trials and Strong Financial Position Support Buy Rating for Context Therapeutics
Express News | Context Therapeutics Q1 EPS $(0.23) Beats $(0.38) Estimate
Express News | Context Therapeutics Inc. Q1 Net Income USD -3.7 Million
No Data